A Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs SUN K706 (Primary)
- Indications Chronic myeloid leukaemia; Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Sun Pharma Advanced Research Company
- 13 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.
- 11 Jun 2018 Status changed from not yet recruiting to recruiting.
- 28 Feb 2018 New trial record